Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:28 PM ET 8-K
Leadership Change e.l.f. Beauty, Inc. ELF

e.l.f. Beauty Leadership Change

e.l.f. Beauty appointed Amit Khetan, the company's current Chief Accounting Officer, to the additional role of principal accounting officer effective November 12, 2026. He succeeds Mandy Fields in this capacity, who will continue to serve as the company's Senior Vice President and Chief Financial Officer. Mr. Khetan will not receive any additional compensation in connection with this appointment.

4:28 PM ET 8-K
Financial Results Research Solutions, Inc. RSSS

Research Solutions Financial Results

Research Solutions reported its first quarter fiscal year 2027 results, highlighted by an 11.5% year-over-year increase in B2B Annual Recurring Revenue (ARR) to $16.5 million. While total revenue slightly decreased to $11.9 million due to lower transaction volume, gross margins improved by 300 basis points to 53.6% as the company continues its strategic shift toward higher-margin platform subscription revenue.

Term
Q1 2027

“Our continued investment in innovation is expanding how researchers discover, access, and engage with scientific literature. Recent launches of Article Galaxy and Scite integrations with ChatGPT, Claude, and Microsoft Copilot bring our capabilities directly into the AI-powered workflows researchers increasingly rely on, making it easier to find trusted evidence and access scholarly content.”

Roy W. Olivier, President and CEO

“Platform revenue accounted for 45% of total revenue this quarter, up from 42% a year ago, reflecting our continued transition toward a higher-margin, recurring revenue model. This evolution is strengthening profitability and operating cash flow, enabling us to reinvest in sales capacity and product innovation to accelerate long-term growth.”

Roy W. Olivier, President and CEO
4:28 PM ET Form 4
Insider Selling LifeStance Health Group, Inc. LFST

LifeStance Health Group Insider TPG Gp a LLC Sells $485M of Stock

TPG Gp a LLC sold 37,233,110 shares of LifeStance Health Group, Inc. at $13.02 a share, worth $485M in total on Nov 12, 2026. Shares held after the trade: 42,458,592 (-46.7%).

Value
$485M
Shares
37,233,110
Price
$13.02
Holding change
-46.7%
Trade date
Nov 12, 2026
4:28 PM ET Form 4
Insider Selling Merck & Co., Inc. MRK

Merck & Co EVP&Pres, Merck Animal Heallth Richard R. DeLuca Sells $8.61M of Stock

Richard R. DeLuca, EVP&Pres, Merck Animal Heallth, sold 58,185 shares of Merck & Co., Inc. at $148.01 a share, worth $8.61M in total on Nov 12, 2026. Shares held after the trade: 112,955 (-34.0%).

Value
$8.61M
Shares
58,185
Price
$148.01
Role
EVP&Pres, Merck Animal Heallth
Holding change
-34.0%
Trade date
Nov 12, 2026
4:28 PM ET Form 4
Insider Buying CV Sciences, Inc. CVSI

CV Sciences Insider Charlie E. Cheever III Buys $45.6K of Stock

Charlie E. Cheever III bought 4,557,721 shares of CV Sciences, Inc. at $0.01 a share, worth $45.6K in total between Nov 4, 2026 and Nov 9, 2026. Shares held after the trade: 31,706,432 (+6.7%).

Value
$45.6K
Shares
4,557,721
Average price
$0.0100
Holding change
+6.7%
Trade date
Nov 4, 2026 to Nov 9, 2026
4:26 PM ET Form 4
Insider Buying Senseonics Holdings, Inc. SENS

Senseonics Holdings Director Douglas A. Roeder Buys $176K of Stock

Douglas A. Roeder, Director, bought 17,041 shares of Senseonics Holdings, Inc. at $10.32 a share, worth $176K in total on Nov 13, 2026. Shares held after the trade: 189,712 (+9.9%).

Value
$176K
Shares
17,040
Price
$10.32
Role
Director
Holding change
+9.9%
Trade date
Nov 13, 2026
4:26 PM ET 10-K
Financial Results Marinemax Inc HZO

Marinemax FY 2026 Results: Net Loss of $8.2M, Loss Narrows

MarineMax is pursuing a growth strategy focused on acquisitions, new retail locations, and digital channel expansion, while navigating risks related to manufacturer approvals and integration. The company faces significant international exposure, particularly regarding foreign currency fluctuations and geopolitical tensions involving suppliers in Italy, Poland, Taiwan, and China.

Key figure
Net loss $8.2M
4:26 PM ET Form 4
Insider Selling Icon PLC ICLR

Icon Insider Ciaran Murray Sells $2M of Stock

Ciaran Murray sold 10,000 shares of Icon PLC at $200.18 a share, worth $2M in total on Nov 12, 2026. Shares held after the trade: 7,000 (-58.8%).

Value
$2M
Shares
10,000
Price
$200.18
Holding change
-58.8%
Trade date
Nov 12, 2026
4:26 PM ET Form 4
Insider Selling Ligand Pharmaceuticals Inc LGND

Ligand Pharmaceuticals Insider Martine Zimmermann Sells $636K of Stock

Martine Zimmermann sold 2,000 shares of Ligand Pharmaceuticals Inc at $318.17 a share, worth $636K in total on Nov 12, 2026. Shares held after the trade: 1,782 (-52.9%).

Value
$636K
Shares
2,000
Price
$318.17
Holding change
-52.9%
Trade date
Nov 12, 2026
4:10 PM ET 10-Q
Financial Results Reliability Inc RLBY

Reliability Q3 2026 Results: Net Loss of $92K, Loss Narrows

Reliability Inc. reported a net loss of $417,000 for the nine months ended September 30, 2026, compared to a $742,000 loss in the prior year period. A significant balance sheet change occurred in mid-2026 when the company acquired 253,292,210 treasury shares in a non-cash settlement of related-party notes receivable, resulting in a total shareholders' deficit of $200,000.

Key figure
Net loss $92K
4:10 PM ET 10-Q
Financial Results HealthLynked Corp HLYK

HealthLynked Q3 2026 Results: Net Loss of $889K, Loss Widens

HealthLynked Corp reported a significant decline in total revenue to $0.83 million for the nine months ended September 30, 2026, compared to $1.76 million in the prior year. The company's net loss widened to $3.33 million, driven largely by a $2.43 million loss on the change in fair value of debt, despite a reduction in total operating expenses.

Key figure
Net loss $889K
4:10 PM ET 10-Q
Financial Results Insight Molecular Diagnostics Inc. IMDX

Insight Molecular Diagnostics Q3 2026 Results: Net Loss of $3.58M, Loss Narrows

Insight Molecular Diagnostics Inc. (iMDx) reported a net loss of $19.1 million for the nine months ended September 30, 2026, an improvement from a $27.3 million loss in the prior year period. The company's financial position remains under pressure with a total shareholders' deficit of $24.2 million and a significant contingent consideration liability of $35.3 million.

Key figure
Net loss $3.58M
4:10 PM ET 10-Q
Financial Results Beasley Broadcast Group Inc BBGI

Beasley Broadcast Group Q3 2026 Results: Net Loss of $12.1M, Loss Widens

Beasley Broadcast Group reported a significant net income of $75.4 million for the nine months ended September 30, 2026, primarily driven by a $91.8 million gain on debt restructure. However, the company faced operational challenges, including a $13.1 million FCC license impairment loss and a decline in net revenue from $152.9 million to $129.5 million year-over-year.

Key figure
Net loss $12.1M
4:10 PM ET 10-Q
Financial Results Elite Performance Holding Corp

Elite Performance Holding Q3 2026 Results: Net Loss of $363K, Loss Widens

Elite Performance Holding Corp. reported zero revenue for the nine months ended September 30, 2026, resulting in a net loss of $784,601. The company's financial position remains strained with a total stockholders' deficit of $3,653,505 and total liabilities of $3,773,501 against only $119,996 in total assets.

Key figure
Net loss $363K
4:10 PM ET 8-K
Financial Results Empire Petroleum Corp EP

Empire Petroleum Financial Results

Empire Petroleum reported third quarter 2026 financial results with total product revenue of $10.4 million and a net loss of $3.5 million. Operationally, the company advanced its Texas development program in the Fort Trinidad Field, successfully re-entering the Wakefield-Harrison GU B #1 well to a depth of 21,006 feet to evaluate deep productive zones.

Term
Q3 2026
4:10 PM ET 10-Q
Financial Results Apimeds Pharmaceuticals US, Inc. APUS

Apimeds Pharmaceuticals US Q3 2026 Results: Turns Profitable, Net Income $33.6M

Apimeds Pharmaceuticals US, Inc. reported a net loss of $21.6 million for the nine months ended September 30, 2026, compared to a $4.8 million loss in the prior year. The company transitioned its operations, recording its first software development revenue of $2.48 million while managing a significant digital asset portfolio valued at $142.4 million.

Key figure
Net income $33.6M
4:10 PM ET 8-K
Investor Presentation Renasant Corp RNST

Renasant Investor Presentation

Renasant Corporation has filed its Third Quarter 2026 Investor Presentation, which management will use for meetings with investors during the fourth quarter of 2026. The presentation provides updates on the company's financial performance, business strategy, and objectives.

4:10 PM ET 10-Q
Financial Results Research Solutions, Inc. RSSS

Research Solutions Q1 2026 Results: Net Income $765K, Up 2.1% YoY

Research Solutions reported total revenue of $11.9 million for the quarter ended September 30, 2026, a slight decrease from $12.3 million in the prior year, though net income improved to $765,252. The company continues to transition towards its SaaS Platform business, which saw revenue growth, while Transaction-based revenue declined.

Key figure
Net income $765K · +2.1% YoY
4:10 PM ET 10-Q
Financial Results Blue Dolphin Energy Co BDCO

Blue Dolphin Energy Q3 2026 Results: Turns Profitable, Net Income $18.9M

Blue Dolphin Energy Company reported 14,921,968 shares of common stock outstanding as of November 16, 2026. The filing highlights a significant corporate structure where Jonathan Carroll and LEH affiliates own 85.1% of the company, and notes the reunification of BOEM and BSEE into the Marine Minerals Administration effective July 2026.

Key figure
Net income $18.9M
4:10 PM ET 10-Q
Financial Results Onfolio Holdings, Inc ONFO

Onfolio Holdings Q3 2026 Results: Net Loss of $12.5M, Loss Widens

Onfolio Holdings reported a significant decrease in total revenue to $4.7 million for the nine months ended September 30, 2026, compared to $8.7 million in the prior year. The company experienced a substantial net loss driven by a massive $15.2 million interest expense, contributing to an accumulated deficit of over $42 million.

Key figure
Net loss $12.5M
4:10 PM ET 10-Q
Financial Results Perfect Moment Ltd. PMNT

Perfect Moment Q2 2026 Results: Net Loss of $2.04M, Loss Widens

Perfect Moment Ltd. reported a net loss of $5.58 million for the six months ended September 30, 2026, a slight improvement from the $5.66 million loss in the prior year period. Total assets increased to $18.27 million from $12.23 million, primarily driven by higher inventory levels and accounts receivable, while the company's shareholders' deficit widened to $3.91 million.

Key figure
Net loss $2.04M
4:10 PM ET 10-Q
Financial Results Neuphoria Therapeutics Inc. NEUP

Neuphoria Therapeutics Q1 2026 Results: Net Loss of $1.43M, Loss Narrows

Neuphoria Therapeutics Inc., formerly Bionomics Limited, completed its re-domiciliation from Australia to Delaware in December 2024. As of November 13, 2026, the company reported 5,411,334 shares of common stock outstanding and is currently pursuing a proposed merger with Scancell Holdings plc.

Key figure
Net loss $1.43M
4:10 PM ET 10-Q
Financial Results Biotricity Inc. BTCY

Biotricity Q2 2026 Results: Net Loss of $808K, Loss Widens

Biotricity Inc. reported revenue of $8.61 million for the six months ended September 30, 2026, a 11% increase year-over-year. Despite achieving positive income from operations of $0.50 million, the company recorded a net loss attributable to common stockholders of $2.02 million due to significant interest expenses and derivative liability adjustments.

Key figure
Net loss $808K
4:10 PM ET 8-K
Shareholder Meeting Automatic Data Processing Inc ADP

Automatic Data Processing Shareholder Meeting

Automatic Data Processing, Inc. held its Annual Meeting of Stockholders on November 11, 2026. Shareholders elected 13 directors to the board, approved executive compensation on an advisory basis, and ratified the appointment of Deloitte & Touche LLP as the independent accounting firm for the fiscal year beginning July 1, 2026.

4:09 PM ET 8-K
Investor Presentation Metagenomi Therapeutics, Inc. MGX

Metagenomi Therapeutics Investor Presentation

Metagenomi Therapeutics, Inc. has furnished a corporate presentation dated November 2026 to provide an update on its precision gene editing pipeline and strategic priorities. The presentation highlights the company's lead candidate MGX-001, upcoming IND filings, and the design of the INTEGR8 clinical trial.

4:09 PM ET 8-K
Financial Results Insight Molecular Diagnostics Inc. IMDX

Insight Molecular Diagnostics Financial Results

Insight Molecular Diagnostics reported Q3 2026 financial results, highlighting revenue of $559,000 and progress on its FDA de novo submission for GraftAssureDx. The company also announced the initiation of patient enrollment in its GALACTIC registry study at UCLA Medical Center to support its decentralized testing thesis.

Term
Q3 2026
4:09 PM ET 8-K
Shareholder Meeting Gold.com, Inc. GOLD

Gold.com Shareholder Meeting

Gold.com, Inc. held its 2026 Annual Meeting of Stockholders on November 12, 2026, where shareholders elected ten directors to serve until the 2027 Annual Meeting. Stockholders also approved, on an advisory basis, the fiscal year 2026 compensation of the company's named executive officers with approximately 91.3% of votes cast in favor.

4:09 PM ET 8-K
Leadership Change Unity Bancorp Inc UNTY

Unity Bancorp Leadership Change

James Donovan retired as First Senior Vice President and Chief Lending Officer of Unity Bank, receiving a $182,000 lump-sum severance payment. Minsu Kim, previously the Bank's Chief Credit Officer, was appointed as the new Chief Lending Officer effective November 12, 2026. The company has commenced a search for a new Chief Credit Officer to fill the vacancy left by Kim's promotion.

4:09 PM ET 8-K
Leadership Change Origin Bancorp, Inc. OBK

Origin Bancorp Leadership Change

Origin Bancorp, Inc. has appointed Derek McGee as Chief Operating Officer, effective November 13, 2026. McGee, who joined the company in 2022 as Chief Legal Counsel, will now oversee legal, enterprise risk, and regulatory coordination functions. The company stated that McGee will not receive any additional compensation or benefits as a result of this promotion.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.